Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00147745 · ClinicalTrials.gov registry record · Phase 2
Effects of Colesevelam on How the Body Responds to Insulin in Patients With Type 2 Diabetes
A Phase 2 study, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
NCT00147745 is a Phase 2 study that has completed, run by Daiichi Sankyo. The registered enrollment target is 36 participants.
The verdict
NCT00147745, a Phase 2 study, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
Study Summary
This study is designed to assess the potential mechanism of action by which WelChol® (colesevelam) may improve blood glucose control in patients with type 2 diabetes
Interventions
- DRUG Colesevelam
- DRUG Colesevelam matching placebo
- DRUG Insulin glargine (Lantus)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2005-06 |
| Est. Completion | 2008-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00147745
The ClinicalTrials.gov registry entry for NCT00147745 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Colesevelam is the first listed.
NCT00147745 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00147745 about?
NCT00147745 is a clinical study titled "Effects of Colesevelam on How the Body Responds to Insulin in Patients With Type 2 Diabetes". This study is designed to assess the potential mechanism of action by which WelChol® (colesevelam) may improve blood glucose control in patients with type 2 diabetes
What is the current status of trial NCT00147745?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2005-06. Estimated completion is 2008-01.
What interventions are being tested in trial NCT00147745?
The interventions under investigation include: Colesevelam (DRUG), Colesevelam matching placebo (DRUG), Insulin glargine (Lantus) (DRUG).
Who is sponsoring clinical trial NCT00147745?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.